C 3885
Latest Information Update: 31 Jan 2008
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis
Most Recent Events
- 11 Mar 2004 Phase-II clinical trials in Allergic rhinitis (unspecified route)